RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:319276

Clear cell renal carcinoma

high confidenceDisorder

Also known as: CCRCC · Clear cell renal cell adenocarcinoma · Clear cell renal cell carcinoma

Publications

44,358

99.6th percentile

Trials

314

Interventional, condition-specific

Researchers

1,115

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

A rare renal tumor arising from proximal tubular epithelial cells of the renal cortex, characterized histologically by malignant epithelial cells with typical clear cytoplasm in conventional staining methods due to a high glycogen and lipid content, featuring a nested growth pattern. Clinically it may present with hematuria, flank pain, anemia or, less commonly, a palpable abdominal mass.

How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (18)

Grawitz tumor · Grawitz tumour · RCC, clear cell adenocarcinoma · clear cell adenocarcinoma of kidney · clear cell adenocarcinoma of the kidney · clear cell adenocarcinoma, kidney · clear cell carcinoma of kidney · clear cell carcinoma of the kidney · clear cell renal cell cancer · clear cell renal cell carcinoma · conventional (clear cell) renal cell adenocarcinoma · conventional (clear cell) renal cell carcinoma · conventional renal cell carcinoma · kidney clear cell adenocarcinoma · kidney clear cell carcinoma · renal cell carcinoma, clear cell adenocarcinoma · renal clear cell adenocarcinoma · renal clear cell carcinoma

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    44,358 matched papers (36,770 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    314 matched on ClinicalTrials.gov (98 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

44,358

44,358 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

44,358 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

36,770 in the last 10 years · high confidence · 99.6th percentile (publications denominator)

Phrase hits: 44,358 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,115

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Wang Y14 papers · 2026

    Department of Radiology, Zhumadian Central Hospital Affiliated to Huanghuai University, Zhumadian, China. 18181239@qq.com.

    Papers in Europe PMC
  2. 02
    Li Y13 papers · 2026

    Department of Pathology and Laboratory Medicine School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.

    Papers in Europe PMC
  3. 03
    Wang J13 papers · 2026

    Senior Department of Urology, Chinese PLA General Hospital, Beijing, China.

    Papers in Europe PMC
  4. 04
    Zhang Y12 papers · 2026

    Department of Urology, Zhongshan Hospital Xiamen University, School of Medicine, Xiamen University, Xiamen 361004, Fujian, China; The Graduate School of Fujian Medical University, Fuzhou 350122, Fujian, China.

    Papers in Europe PMC
  5. 05
    Li J11 papers · 2026

    The First Clinical Medical School of Shanxi Medical University, No. 56 Xinjian South Road, Yingze District, Taiyuan, Shanxi 030001, China (D.L., J.L., Z.W., Z.G., H.F., J.G., W.S.); Department of Urology, First Hospital of Shanxi Medical University, No. 85 Jiefang South Road, Yingze District, Taiyuan, Shanxi 030001, China (D.L., J.L., Z.W., Z.G., H.F., J.G., W.S.).

    Papers in Europe PMC
  6. 06
    Liu Y11 papers · 2026

    Department of Urology, The Fifth Affiliated Hospital, Southern Medical University, Guangzhou, Guangdong, 510900, China.

    Papers in Europe PMC
  7. 07
    Chen J9 papers · 2026

    Department of Pathology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.

    Papers in Europe PMC
  8. 08
    Li X9 papers · 2026

    Affiliated Meizhou Hospital of Shantou University Medical College, Meizhou, China.

    Papers in Europe PMC
  9. 09
    Zhang H9 papers · 2026

    The First College of Clinical Medical Science, China Three Gorges University, Yichang, P.R. China.

    Papers in Europe PMC
  10. 10
    Chen X8 papers · 2026

    Senior Department of Urology, Chinese PLA General Hospital, Beijing, China.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

314

interventional trials for this specific condition

314 interventional trials matched this specific condition name; 98 currently recruiting in our sample.

Data as of 27 July 2026

314 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 99.6th percentile).

high confidence · 99.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

314 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

25 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Clear cell renal carcinoma" OR "CCRCC" OR "Clear cell renal cell adenocarcinoma" OR "Clear cell renal cell carcinoma" OR "Grawitz tumor" OR "Grawitz tumour" OR "RCC, clear cell adenocarcinoma" OR "clear cell adenocarcinoma of kidney" OR "clear cell adenocarcinoma of the kidney" OR "clear cell adenocarcinoma, kidney" OR "clear cell carcinoma of kidney" OR "clear cell carcinoma of the kidney" OR "clear cell renal cell cancer" OR "conventional (clear cell) renal cell adenocarcinoma" OR "conventional (clear cell) renal cell carcinoma" OR "conventional renal cell carcinoma" OR "kidney clear cell adenocarcinoma" OR "kidney clear cell carcinoma" OR "renal cell carcinoma, clear cell adenocarcinoma" OR "renal clear cell adenocarcinoma" OR "renal clear cell carcinoma"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Clear cell renal carcinoma" OR "CCRCC" OR "Clear cell renal cell adenocarcinoma" OR "Clear cell renal cell carcinoma" OR "Grawitz tumor" OR "Grawitz tumour" OR "RCC, clear cell adenocarcinoma" OR "clear cell adenocarcinoma of kidney" OR "clear cell adenocarcinoma of the kidney" OR "clear cell adenocarcinoma, kidney" OR "clear cell carcinoma of kidney" OR "clear cell carcinoma of the kidney" OR "clear cell renal cell cancer" OR "conventional (clear cell) renal cell adenocarcinoma" OR "conventional (clear cell) renal cell carcinoma" OR "conventional renal cell carcinoma" OR "kidney clear cell adenocarcinoma" OR "kidney clear cell carcinoma" OR "renal cell carcinoma, clear cell adenocarcinoma" OR "renal clear cell adenocarcinoma" OR "renal clear cell carcinoma"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 314 interventional · 25 observational · 1 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T13:22:29.144Z